13.53
price down icon3.01%   -0.42
pre-market  プレマーケット:  14.00   0.47   +3.47%
loading
前日終値:
$13.95
開ける:
$14.07
24時間の取引高:
330.27K
Relative Volume:
1.92
時価総額:
$393.43M
収益:
$69.21M
当期純損益:
$-61.98M
株価収益率:
-5.2145
EPS:
-2.5947
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-1.67%
1か月 パフォーマンス:
+1.65%
6か月 パフォーマンス:
-2.94%
1年 パフォーマンス:
+132.87%
1日の値動き範囲:
Value
$13.38
$14.11
1週間の範囲:
Value
$13.38
$14.40
52週間の値動き範囲:
Value
$5.70
$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
名前
Enanta Pharmaceuticals Inc
Name
セクター
Healthcare (1111)
Name
電話
617 607 0800
Name
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
職員
120
Name
Twitter
@EnantaPharma
Name
次回の収益日
2026-05-11
Name
最新のSEC提出書
Name
ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ENTA icon
ENTA
Enanta Pharmaceuticals Inc
13.53 405.64M 69.21M -61.98M -18.46M -2.5947
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.93 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.62 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.43 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-26 開始されました Rodman & Renshaw Buy
2025-11-14 開始されました JP Morgan Overweight
2025-10-01 アップグレード Jefferies Hold → Buy
2025-07-28 再開されました H.C. Wainwright Buy
2023-08-09 ダウングレード JP Morgan Neutral → Underweight
2023-08-08 ダウングレード Jefferies Buy → Hold
2022-12-09 開始されました H.C. Wainwright Buy
2022-07-06 アップグレード Evercore ISI In-line → Outperform
2022-06-01 アップグレード Evercore ISI Underperform → In-line
2021-10-07 開始されました Jefferies Buy
2021-09-09 開始されました SVB Leerink Mkt Perform
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2020-11-24 開始されました Evercore ISI Underperform
2020-08-28 再開されました ROTH Capital Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-27 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 アップグレード Robert W. Baird Neutral → Outperform
2019-11-22 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 ダウングレード JP Morgan Neutral → Underweight
2019-05-24 開始されました Wolfe Research Outperform
2019-04-23 アップグレード Berenberg Hold → Buy
2018-12-13 開始されました Berenberg Hold
2018-06-06 開始されました ROTH Capital Buy
2018-02-08 ダウングレード JP Morgan Overweight → Neutral
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-11-21 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-07-11 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました Barclays Underweight
2015-10-23 ダウングレード Barclays Equal Weight → Underweight
2015-10-23 アップグレード JMP Securities Mkt Perform → Mkt Outperform
すべてを表示

Enanta Pharmaceuticals Inc (ENTA) 最新ニュース

pulisher
May 19, 2026

Discipline and Rules-Based Execution in ENTA Response - Stock Traders Daily

May 19, 2026
pulisher
May 19, 2026

Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews

May 19, 2026
pulisher
May 14, 2026

Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives - Sahm

May 14, 2026
pulisher
May 13, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st

May 13, 2026
pulisher
May 13, 2026

Enanta Pharmaceuticals Q2 2026 Financial Results and Management Discussion – 10-Q Report Highlights - Minichart

May 13, 2026
pulisher
May 13, 2026

ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary - TradingView

May 13, 2026
pulisher
May 13, 2026

Enanta Pharmaceuticals (NASDAQ: ENTA) trims losses on higher HCV royalties and lower R&D - Stock Titan

May 13, 2026
pulisher
May 12, 2026

Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

May 12, 2026
pulisher
May 12, 2026

Enanta Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

May 12, 2026
pulisher
May 12, 2026

ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill

May 12, 2026
pulisher
May 11, 2026

Enanta (ENTA) Reports Strong Q2 Revenue and Progress in Clinical Trials - GuruFocus

May 11, 2026
pulisher
May 11, 2026

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com

May 11, 2026
pulisher
May 11, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q2 FY26 Beat? - GuruFocus

May 11, 2026
pulisher
May 11, 2026

ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus - ChartMill

May 11, 2026
pulisher
May 11, 2026

ENANTA PHARMACEUTICALS ($ENTA) Releases Q2 2026 Earnings - Quiver Quantitative

May 11, 2026
pulisher
May 11, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Weekly Voice

May 11, 2026
pulisher
May 11, 2026

Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView

May 11, 2026
pulisher
May 11, 2026

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - marketscreener.com

May 11, 2026
pulisher
May 11, 2026

[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan

May 11, 2026
pulisher
May 11, 2026

MSN Money - MSN

May 11, 2026
pulisher
May 08, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

May 08, 2026
pulisher
May 08, 2026

Behavioral Patterns of ENTA and Institutional Flows - Stock Traders Daily

May 08, 2026
pulisher
May 07, 2026

Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance

May 07, 2026
pulisher
May 04, 2026

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Progr - PharmiWeb.com

May 04, 2026
pulisher
May 04, 2026

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - BioSpace

May 04, 2026
pulisher
Apr 27, 2026

Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 27, 2026
pulisher
Apr 24, 2026

ENTA Price Today: Enanta Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 24, 2026
pulisher
Apr 23, 2026

ENTA (Enanta Pharmaceuticals Inc.) posts 49 percent narrower Q1 2026 loss than expected, shares fall 3.37 percent on slight revenue decline.Management Guidance - Xã Thanh Hà

Apr 23, 2026
pulisher
Apr 16, 2026

How (ENTA) Movements Inform Risk Allocation Models - Stock Traders Daily

Apr 16, 2026
pulisher
Apr 16, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat

Apr 16, 2026
pulisher
Apr 13, 2026

Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus

Apr 13, 2026
pulisher
Apr 13, 2026

Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia

Apr 13, 2026
pulisher
Apr 13, 2026

Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 13, 2026

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace

Apr 13, 2026
pulisher
Apr 13, 2026

Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com

Apr 13, 2026
pulisher
Apr 13, 2026

Enanta doses first patient in phase 1 trial of urticaria drug By Investing.com - Investing.com South Africa

Apr 13, 2026
pulisher
Apr 10, 2026

Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 08, 2026

Are investors bullish on Enanta Pharmaceuticals (ENTA) Stock | ENTA Q4 Earnings: Beats Estimates by $0.40 - Newser

Apr 08, 2026
pulisher
Apr 07, 2026

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com

Apr 07, 2026
pulisher
Apr 07, 2026

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire

Apr 07, 2026
pulisher
Apr 06, 2026

Is Enanta Pharmaceuticals (ENTA) Stock Suitable for 2026 | Price at $13.18, Up 0.27%Size Factor - Newser

Apr 06, 2026
pulisher
Apr 05, 2026

Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily

Apr 05, 2026
pulisher
Apr 03, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 03, 2026
pulisher
Apr 03, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat

Apr 03, 2026

Enanta Pharmaceuticals Inc (ENTA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
大文字化:     |  ボリューム (24 時間):